One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...

CNBC's Becky Quick reports on the progress of KJ Muldoon, the first patient to receive a personalized CRISPR-based gene ...

Vector-borne diseases (VBDs) represent a critical challenge in infectious disease control due to their complex transmission dynamics, diverse vector ...

CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access and exposing fragile gene‑therapy infrastructure.

In a world where agriculture is confronted with unprecedented challenges—such as climate variability, emerging pathogens, and ...

"Gene editing takes centre stage in FDA’s new rare disease approval pathway" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The rise of gene editing forces regulators to confront a difficult question: How to protect fair play in the age of genomic medicine.

CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its ...

A chubby-cheeked baby called KJ made medical history last year. Faced with a life-threatening metabolic disease, KJ’s doctors at Children’s Hospital of Philadelphia sprinted to create a personalized ...

In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...

Scientists are developing a new CRISPR-based system that uses caffeine to precisely control gene activity inside cells. By turning gene editing on and off with familiar compounds, the method points ...